Therefore, the biased ligands for MC4R that selectively activate Gαq signaling to decrease food intake but not trigger Gαs signaling with cardiovascular side effects might be better drug candidates for obesity treatment [21]. This evidence concerns the gene MC4R and obesity disorder.